Esophageal malignant tumor
Conditions
Interventions
Experimental group:Angotini + paclitaxel + cisplatin
Sponsors
Henan Provincial Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; 2. Male or female patients aged 18 to 70 years; 3. Histological or cytological diagnosis of esophageal squamous cell carcinoma; 4. Resectable and measurable esophageal squamous cell carcinoma as specified in the 2021 CSCO guidelines; 5. Life expectancy of at least 1 year; 6. ECOG score: 0-2 points; 7. The main organs function normally.
Exclusion criteria
Exclusion criteria: 1. Suffering from or currently suffering from other malignant tumors within 5 years; 2. Those who are known to be allergic to anlotinib hydrochloride capsules; 3. Previous use of other anti-angiogenic drugs; 4. Comorbid diseases and medical history; 5. History of HIV or liver disease found in physical examination and laboratory examination; 6. Women of childbearing age should have a positive pregnancy test (serum or urine) result within 7 days before enrollment; men, refuse to use appropriate methods of contraception during the test and 8 weeks after the last administration of the test drug; 7. Pregnant women; 8. Participating in other clinical studies (except non-interventional studies) or less than 4 weeks from the end of the previous clinical study; 9. Patients who are judged by the investigator to be unsuitable to participate in the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic Complete Response; | — |
Secondary
| Measure | Time frame |
|---|---|
| R0 resection rate;Disease-free survival;Drug safety; | — |
Countries
China
Contacts
Public ContactJiang Gongqian
Henan Provincial Chest Hospital
Outcome results
None listed